Renovaro to Acquire Predictive Oncology in All-Stock Transaction
Renovaro (NASDAQ: RENB) has announced a binding LOI to acquire Predictive Oncology (NASDAQ: POAI) in an all-stock transaction. The acquisition provides Renovaro access to a significant biobank containing over 150,000 tumor specimens and 200,000 pathology slides, along with decades of longitudinal drug response data.
The merger combines Predictive Oncology's AI-driven multi-omic drug discovery platform with Renovaro's AI Cube technology, aiming to advance cancer diagnostics and early drug discovery. Predictive Oncology's platform has demonstrated 92% accuracy in predicting tumor-drug response, potentially enabling a decision support platform launch for medical oncologists in 2025.
Key synergies include access to a state-of-the-art CLIA, NYSDOH, and CA-certified laboratory, accelerated biomarker discovery capabilities, and enhanced clinical trial optimization. The combined entity aims to deliver a global point-of-care solution for cancer, integrating diagnostics, early detection, and personalized therapies.
Renovaro (NASDAQ: RENB) ha annunciato una LOI vincolante per acquisire Predictive Oncology (NASDAQ: POAI) in un'operazione interamente in azioni. L'acquisizione consente a Renovaro di accedere a una biobanca significativa contenente oltre 150.000 campioni tumorali e 200.000 preparati patologici, insieme a decenni di dati longitudinali sulla risposta ai farmaci.
La fusione combina la piattaforma di scoperta di farmaci multi-omica guidata dall'IA di Predictive Oncology con la tecnologia AI Cube di Renovaro, con l'obiettivo di migliorare la diagnostica del cancro e la scoperta precoce di farmaci. La piattaforma di Predictive Oncology ha dimostrato una precisione del 92% nel prevedere la risposta tumore-farmaco, potenzialmente permettendo il lancio di una piattaforma di supporto decisionale per gli oncologi medici nel 2025.
Le sinergie chiave includono l'accesso a un laboratorio certificato CLIA, NYSDOH e CA all'avanguardia, capacità accelerate di scoperta di biomarcatori e un'ottimizzazione migliorata dei trial clinici. L'entità combinata mira a fornire una soluzione globale per la cura del cancro, integrando diagnostica, rilevamento precoce e terapie personalizzate.
Renovaro (NASDAQ: RENB) ha anunciado una LOI vinculante para adquirir Predictive Oncology (NASDAQ: POAI) en una transacción totalmente en acciones. La adquisición proporciona a Renovaro acceso a un biobanco significativo que contiene más de 150,000 muestras tumorales y 200,000 diapositivas de patología, junto con décadas de datos longitudinales sobre la respuesta a medicamentos.
La fusión combina la plataforma de descubrimiento de medicamentos multi-ómica impulsada por IA de Predictive Oncology con la tecnología AI Cube de Renovaro, con el objetivo de avanzar en los diagnósticos del cáncer y el descubrimiento temprano de medicamentos. La plataforma de Predictive Oncology ha demostrado un 92% de precisión en la predicción de la respuesta tumoral a fármacos, lo que potencialmente habilitaría el lanzamiento de una plataforma de apoyo a la decisión para oncólogos médicos en 2025.
Las sinergias clave incluyen acceso a un laboratorio certificado CLIA, NYSDOH y CA de última generación, capacidades aceleradas de descubrimiento de biomarcadores y una optimización mejorada de ensayos clínicos. La entidad combinada tiene como objetivo ofrecer una solución global de atención para el cáncer, integrando diagnósticos, detección temprana y terapias personalizadas.
Renovaro (NASDAQ: RENB)는 Predictive Oncology (NASDAQ: POAI)를 전액 주식 거래로 인수하기 위한 구속력 있는 LOI를 발표했습니다. 이번 인수를 통해 Renovaro는 150,000개 이상의 종양 샘플과 200,000개의 병리 슬라이드를 포함한 중요한 바이오뱅크에 접근할 수 있으며, 수십 년 간의 약물 반응 데이터도 확보할 수 있습니다.
이번 합병은 Predictive Oncology의 AI 기반 다중 오믹 약물 발견 플랫폼과 Renovaro의 AI Cube 기술을 결합하여 암 진단 및 초기 약물 발견을 발전시키는 것을 목표로 합니다. Predictive Oncology의 플랫폼은 종양-약물 반응 예측에서 92%의 정확도를 입증하였으며, 이는 2025년에는 의학 종양학자를 위한 의사 결정 지원 플랫폼 출시를 가능하게 할 것입니다.
주요 시너지 효과로는 최신 CLIA, NYSDOH 및 CA 인증 실험실 접근, 가속화된 바이오마커 발견 능력 및 향상된 임상 시험 최적화가 포함됩니다. 결합된 엔터프라이즈는 진단, 조기 발견 및 개인 맞춤형 치료를 통합하여 암에 대한 글로벌 진료 솔루션을 제공하는 것을 목표로 합니다.
Renovaro (NASDAQ: RENB) a annoncé une LOI contraignante pour acquérir Predictive Oncology (NASDAQ: POAI) dans le cadre d'une transaction entièrement en actions. Cette acquisition permet à Renovaro d'accéder à une biobanque significative contenant plus de 150 000 échantillons tumoraux et 200 000 lames de pathologie, ainsi que des données longitudinales sur la réponse aux médicaments accumulées sur des décennies.
La fusion combine la plateforme de découverte de médicaments multi-omiques basée sur l'IA de Predictive Oncology avec la technologie AI Cube de Renovaro, visant à faire progresser le diagnostic du cancer et la découverte précoce de médicaments. La plateforme de Predictive Oncology a démontré une précision de 92 % dans la prédiction de la réponse aux médicaments des tumeurs, permettant ainsi potentiellement le lancement d'une plateforme de soutien à la décision pour les oncologues médicaux en 2025.
Les synergies clés incluent l'accès à un laboratoire de pointe certifié CLIA, NYSDOH et CA, des capacités de découverte de biomarqueurs accélérées et une optimisation améliorée des essais cliniques. L'entité combinée vise à offrir une solution mondiale de soins du cancer, intégrant diagnostic, détection précoce et thérapies personnalisées.
Renovaro (NASDAQ: RENB) hat eine verbindliche LOI zur Übernahme von Predictive Oncology (NASDAQ: POAI) in einer rein aktienbasierten Transaktion angekündigt. Die Akquisition verschafft Renovaro Zugang zu einer bedeutenden Biobank mit über 150.000 Tumorproben und 200.000 Pathologieschnitten sowie jahrzehntelangen longitudinalen Medikamentenreaktionsdaten.
Die Fusion kombiniert die KI-gesteuerte multi-omische Arzneimittelentdeckungsplattform von Predictive Oncology mit der AI Cube-Technologie von Renovaro, um die Krebsdiagnostik und die frühe Arzneimittelentdeckung voranzutreiben. Die Plattform von Predictive Oncology hat eine Genauigkeit von 92 % bei der Vorhersage der Tumor-Arzneimittel-Reaktion gezeigt, was möglicherweise die Einführung einer Entscheidungsunterstützungsplattform für medizinische Onkologen im Jahr 2025 ermöglichen könnte.
Zu den wichtigsten Synergien gehören der Zugang zu einem modernen, CLIA-, NYSDOH- und CA-zertifizierten Labor, beschleunigte Biomarker-Entdeckungsfähigkeiten sowie verbesserte klinische Studienoptimierung. Das kombinierte Unternehmen strebt an, eine globale Lösung für die Versorgung mit Krebs zu bieten, die Diagnostik, Früherkennung und personalisierte Therapien integriert.
- Access to extensive biobank with 150,000 tumor specimens and 200,000 pathology slides
- AI platform with 92% accuracy in tumor-drug response prediction
- Access to state-of-the-art CLIA, NYSDOH, and CA-certified laboratory
- Enhanced capabilities for biomarker discovery and clinical trial optimization
- Expansion potential into European markets
- All-stock transaction structure may lead to shareholder dilution
- Integration risks between different AI platforms and technologies
- Execution risk in combining different organizational operations
Insights
This strategic acquisition marks a pivotal moment in cancer diagnostics and AI-driven therapeutics. The all-stock transaction combines Predictive Oncology's 150,000+ tumor biobank with Renovaro's AI capabilities, creating substantial value potential. The deal structure using preferred stock suggests careful consideration of dilution effects while maintaining capital structure flexibility.
The merger's strategic value lies in three key areas: immediate access to an extensive biodata repository, established CLIA-certified laboratory infrastructure and proven AI/ML platform with 92% accuracy in tumor-drug response prediction. For a company with a market cap of
The combined entity's enhanced capabilities in both liquid biopsy and solid tumor analysis create a comprehensive cancer diagnostics platform, positioning it strongly in the rapidly growing precision oncology market, estimated at
The integration of Predictive Oncology's biobank and Renovaro's AI Cube platform represents a significant technological leap in cancer diagnostics. The key differentiator is the combination of historical patient data with advanced AI capabilities, enabling more accurate treatment predictions and personalized therapy selection.
The synergistic value emerges from:
- Accelerated biomarker discovery through extensive tumor sample access
- Enhanced clinical trial optimization capabilities
- Streamlined European market entry through existing infrastructure
This merger represents a significant advancement in AI-driven healthcare solutions. The combination of Predictive Oncology's proven AI/ML platform with Renovaro's AI Cube creates a powerful multi-omic analysis capability that could revolutionize cancer treatment approaches. The extensive dataset of 150,000 tumor specimens and 200,000 pathology slides provides important training data for AI model refinement.
The integration of liquid biopsy technology with solid tumor analysis, powered by advanced AI, positions the company to develop more comprehensive and accurate cancer detection and monitoring solutions. The potential for in silico modeling and biomarker discovery could significantly reduce drug development timelines and costs while improving success rates in clinical trials.
Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data
Data provides a critical pathway to progress AI using the high-speed computing power provided through collaboration with Nebul
Combines Predictive Oncology’s AI-driven multi-omic drug discovery platform with Renovaro’s AI Cube multi-omic artificial intelligence to advance both cancer diagnostics and early drug discovery
Planned test launch to assist physicians in individualizing cancer therapy to improve treatment outcomes
LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced it has entered into a binding LOI to acquire Predictive Oncology (NASDAQ: POAI) in an all-stock transaction.
David Weinstein, Chief Executive Officer of Renovaro, commented, “Renovaro is on a quest to offer cancer patients early diagnostic options, treatment protocols, and recurrence monitoring. Predictive Oncology will enhance our capabilities by assisting oncologists with patient specific diagnostic and therapeutic clinical support data. Predictive Oncology’s proprietary AI/ML platform has been proven to predict tumor-drug response with
Raymond Vennare, Chief Executive Officer of Predictive Oncology, added, “We recognize that by integrating Predictive Oncology’s AI-driven drug discovery platform and vast biobank of more than 150,000 patient tumor samples, 200,000 pathology slides and decades of longitudinal drug response data with Renovaro’s multi-disciplinary artificial intelligence, multi-omics and multi-modal data expertise, we are opening to door to diagnostic, therapeutic and drug discovery possibilities that we otherwise would never have considered.”
Short-Term Synergies
- By leveraging Predictive Oncology’s extensive biobank of 150,000 tumor samples, Renovaro gains an invaluable resource to accelerate biomarker discovery, clinical trial optimization and clinical decision support tools across multiple cancer types.
- The combined organization will have a state-of-the-art CLIA, NYSDOH, and CA-certified laboratory staffed by a highly experienced team.
- Infrastructure streamlines Renovaro’s development, validation, and rollout of new diagnostic tests in Europe, improving speed to market and expanding global reach.
- Introduces novel in vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy to the European markets.
- Enables the company to collaborate across multi-omic platforms for drug discovery.
Long-Term Vision
- Renovaro’s partnership with Predictive Oncology creates a powerful foundation for delivering a global point-of-care solution for cancer.
- By integrating Predictive Oncology’s AI-driven small molecule solid tumor expertise with Renovaro’s AI-powered liquid biopsy and cancer vaccine programs, we envision an opportunity to provide patients with a comprehensive, end-to-end solution from diagnostics and early detection to personalized therapies, in silico modeling and biomarker discovery.
- First-in-class, full-stack clinical service has the potential to advance cancer therapy at every stage of the patient’s journey, improving outcomes and reducing costs.
Predictive Oncology announced on November 13, 2024, that the company’s Board of Directors, working with a strategic advisor, had initiated a process to evaluate a broad range of strategic alternatives intended to maximize shareholder value and issued an update on December 3, 2024, stating the Company was engaged in productive discussions with multiple interested parties and looked forward to the timely completion of this process.
Transaction Details
Renovaro will acquire
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early biomarker and drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s proprietary AI/ML platform has been scientifically validated to predict with
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
karen@renovarocube.com and STarsh@Renovarogroup.com
FAQ
What are the key assets Renovaro (RENB) gains from acquiring Predictive Oncology?
When does Renovaro (RENB) plan to launch its oncologist decision support platform?
How will the Renovaro (RENB) acquisition affect European market expansion?
What is the accuracy rate of Predictive Oncology's AI platform being acquired by Renovaro (RENB)?
How will Renovaro (RENB) finance the acquisition of Predictive Oncology?
